JF
MRSN

Jump Financial’s Mersana Therapeutics MRSN Stock Holding History

Jump Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-453
Closed -$3.35K – 2062
2025
Q2 		$3.35K Buy
+453
New +$3.98K ﹤0.01% 1755
2024
Q3 		– Sell
-3,222
Closed -$162K – 1943
2024
Q2 		$162K Buy
3,222
+2,572
+396% +$186K ﹤0.01% 1590
2024
Q1 		$72.8K Buy
+650
New +$64.6K ﹤0.01% 1816
2023
Q3 		– Sell
-896
Closed -$73.7K – 2110
2023
Q2 		$73.7K Buy
+896
New +$131K ﹤0.01% 1694
2023
Q1 		– Sell
-2,585
Closed -$379K – 1880
2022
Q4 		$379K Buy
2,585
+801
+45% +$135K 0.02% 902
2022
Q3 		$301K Buy
+1,784
New +$290K 0.01% 1148
2022
Q2 		– Sell
-2,700
Closed -$269K – 1864
2022
Q1 		$269K Sell
2,700
-216
-7% -$25.2K 0.01% 1128
2021
Q4 		$453K Buy
+2,916
New +$567K 0.03% 700
2021
Q2 		– Sell
-1,013
Closed -$409K – 1285
2021
Q1 		$409K Buy
+1,013
New +$491K 0.04% 482

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jump Financial's MRSN Position: Q3 2025 in Review

Jump Financial sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 453 shares — an estimated $3.35K sold.

Jump Financial first reported a position in MRSN in Q1 2021 and held it in 9 quarters. The position peaked at $453K in Q4 2021. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Jump Financial reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jump Financial sold 453 Mersana Therapeutics shares in Q3 2025, an estimated $3.35K.
  • Jump Financial first reported a position in Mersana Therapeutics in Q1 2021 and held it in 9 quarters.
  • Jump Financial's Mersana Therapeutics position peaked at $453K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.